Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971230 | 0.95 | LMNA (0.46) | KDM4ELMNASMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL4968521 | 0.87 | KDM4E (0.54) | KDM4ELMNASMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL4970637 | 0.86 | PKM (0.56) | KDM4ELMNASMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL4966298 | 0.83 | KDM4E (0.53) | KDM4ELMNASMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL4970011 | 0.82 | PKM (0.56) | KDM4ELMNASMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL4969198 | 0.81 | FFAR4 (0.35) | MEN1MAPTKMT2A | |
| SCHEMBL5722710 | 0.81 | MAPT (0.59) | KDM4ELMNAMAPK1HTTPKM | |
| SCHEMBL8921186 | 0.71 | PKM (0.64) | KDM4ELMNASMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL25674637 | 0.70 | MAPT (0.44) | KDM4ESMN1; SMN2HTTMEN1GAA | |
| SCHEMBL4966207 | 0.70 | KDM4E (0.69) | KDM4ELMNASMN1; SMN2MAPK1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670770-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670770-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030733-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | F12, H1-3, H1-4 | KDM4E 1841/4885LMNA 2120/4885SMN1; SMN2 1918/4885 |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | KDM4E 2030/4885LMNA 1900/4885SMN1; SMN2 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.